2026 Year 7 Moon 10 The Inaugural Meeting of the Artificial Intelligence Committee of the Shanghai Federation of Industry and Commerce Biomedical Chamber of Commerce and its First Meeting of the First Committee were solemnly held. Through democratic elections at the meeting,Zhiyao Yuanchuang was officially elected as a vice chairman unit of the Artificial Intelligence Special Committee.Together with industry leaders such as Hengrui Medicine, Fosun Pharma, Huawei, and United Imaging Healthcare, they form the core leadership team of the special committee to jointly promote the deep integration of digital technology with the entire biopharmaceutical industry chain.

This Artificial Intelligence Special Committee meeting is a response by the Shanghai Federation of Industry and Commerce Biomedical Chamber of Commerce to the relevant instructions from the municipal government and to seize opportunities.AIA key strategic move to capitalize on opportunities in pharmaceutical development. The preparatory work for the Special Committee is led by Hengrui Medicine, in conjunction with... 8 With the joint efforts of leading companies in the industry chain, and after multiple rounds of discussion and resource selection, the final decision was made. 27 Innovative pharmaceutical companiesAITechnology companies, medical device enterprises, and research institutions became the first batch of member units. The new leadership team covers innovative pharmaceuticals, computing infrastructure, and medical imaging.AINew drug development,CROA complete track including services, enabling biopharmaceutical entities to connect with...AITwo-way collaboration among technology service providers.

As a domestic focusAIAs a representative science and technology innovation enterprise driving peptide and protein drug design, the fact that Zhiyao Yuanchuang was selected as a vice-chairman unit fully reflects the industry's high regard for the company.AIThe company has received high recognition for its technological strength, industrial practice, and innovative potential in the field of new drug development. Since its inception, Zhiyao Yuanchuang has focused on...AIDriving the development of protein and peptide drugs, and building an independent and controllable end-to-end process.AIThe drug design platform continuously promotes algorithm innovation, pipeline development and industrial application, and deeply participates in solving common industry problems such as long drug development cycles, high costs and data fragmentation.

Looking to the future, Smart Pharma will rely on the platform of the Special Committee.Actively participate in breaking down industrial chain barriers and building an open and collaborative ecosystem.AIPharmaceutical innovation ecosystem; focusing on cutting-edge aspects such as target discovery and molecular design, with practical and reusable solutions.AINew drug development solutions; deep involvement in the discussion and formulation of pharmaceutical R&D data standards and industry standards, helping to solve the pain point of data silos in the industry; strengthening collaboration with pharmaceutical companies, medical device companies, and research institutions to promote...AIThe technology is extending from early drug development to clinical applications.

Meanwhile, the company will actively cooperate with the Special Committee's regular industry salons, special research projects, and joint research initiatives, and continuously refine its work.AITo address the development needs of pharmaceutical companies, and through the communication channels between the chamber of commerce and government, we will offer suggestions for improving Shanghai's policies on the intelligent biomedicine industry, and work together to help Shanghai build a globally influential innovation hub for intelligent medicine.

[About Smart Pharma Innovation]

The innovative drug discovery was developed by two senior professors from Shanghai Jiao Tong University.2023Year11Founded jointly by Yue, it is aAIDriving peptide and protein drug designBiotechEnterprises. Companies have built coverage"Skeleton Design—Sequence generation—Structural Prediction—Function Filtering"With full-chain technological capabilities, it has independently developed three major technologies.AIComputing platform——TransProteinPeptide and protein design platform (integrated)GPDL、GPDandIDPFold(and other core algorithms)TransCyclicPeptideA dedicated design platform for cyclic peptide drugs, andTransMoleculeA small molecule drug discovery platform, forming a complete system covering macromolecules, peptides, cyclic peptides, and small molecules.AIDrug design matrix. Based on a self-developed algorithm matrix, the platform can complete the design and screening of tens of thousands of sequences within approximately two weeks, with a first-round wet experimental success rate of [percentage missing].52%Compared with traditional methods, it improves by nearly50The company is currently advancing multiple proprietary pipelines in the fields of metabolic, neurological, and immune diseases, and is collaborating with several listed pharmaceutical companies on projects, providing one-stop solutions from algorithm design to experimental validation.